Bates S M, Weitz J I
McMaster University, Hamilton, Ontario, Canada.
Cardiovasc Res. 1999 Feb;41(2):418-32. doi: 10.1016/s0008-6363(98)00323-x.
Many of the acute coronary ischemic syndromes are triggered by spontaneous or mechanical disruption of atherosclerotic plaques with resultant activation of platelets and coagulation. Given the central role of platelets and thrombin in arterial thrombosis, current strategies for its prevention and treatment focus on both inhibition of platelet aggregation and control of thrombin generation and activity. Although aspirin and unfractionated heparin are the cornerstones of current treatment strategies, both have limitations. This review will describe these limitations and discuss new antithrombotic agents developed for use in acute coronary ischemic syndromes and as adjuncts for percutaneous coronary revascularization procedures.
许多急性冠状动脉缺血综合征是由动脉粥样硬化斑块的自发性或机械性破裂引发的，进而导致血小板激活和凝血。鉴于血小板和凝血酶在动脉血栓形成中的核心作用，目前其预防和治疗策略聚焦于抑制血小板聚集以及控制凝血酶的生成和活性。尽管阿司匹林和普通肝素是当前治疗策略的基石，但两者均存在局限性。本综述将描述这些局限性，并讨论为用于急性冠状动脉缺血综合征以及作为经皮冠状动脉血运重建术辅助药物而研发的新型抗血栓药物。
